Leqvio, also known as inclisiran, is a medication administered via injection to lower low-density lipoprotein cholesterol (LDL-C), often referred to as “bad” cholesterol. The drug’s high price point, approximately $12,000 for a course of two initial injections followed by maintenance doses, stems from a complex interplay of factors typical of novel pharmaceutical products. These include research and development expenses, manufacturing costs, clinical trial investments, and market dynamics.
The elevated cost is justified, according to the manufacturer and supporting stakeholders, by several factors. Firstly, Leqvio offers a semi-annual dosing schedule, which can improve patient adherence compared to daily oral medications. This enhanced adherence potentially translates to better long-term cardiovascular outcomes, thereby reducing the overall burden of cardiovascular disease. The drug’s innovative mechanism of action, RNA interference, also contributes to the premium pricing, as it represents a significant advancement in cholesterol management. The patent protection granted to the drug allows the manufacturer a period of market exclusivity to recoup its investments. Historically, pharmaceutical companies invest heavily in research, development, and navigating regulatory approval processes, all of which influence the final cost of a medication.
